Switch theme
Sign up to access all valuation multiples
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Viaskin targets specific antigen-presenting immune cells in the skin, called Langerhans cells, that capture the antigen and migrate to the lymph node to activate the immune system without passage of the antigen into the bloodstream, minimizing systemic exposure in the body. Its main product candidate is Viaskin Peanut for the treatment of peanut-allergic patients.
2002
104
LTM Revenue $3.5M
LTM EBITDA -$156M
$158M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
DBV Technologies has a last 12-month revenue of $3.5M and a last 12-month EBITDA of -$156M.
In the most recent fiscal year, DBV Technologies achieved revenue of n/a and an EBITDA of -$72.4M.
DBV Technologies expects next 12-month revenue of XXX and NTM EBITDA of XXX
See DBV Technologies valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | n/a | n/a | XXX | XXX | XXX |
| Gross Profit | n/a | n/a | XXX | XXX | XXX |
| Gross Margin | NaN% | NaN% | XXX | XXX | XXX |
| EBITDA | -$89.7M | -$72.4M | XXX | XXX | XXX |
| EBITDA Margin | -Infinity% | -Infinity% | XXX | XXX | XXX |
| Net Profit | -$105M | -$103M | XXX | XXX | XXX |
| Net Margin | -Infinity% | -Infinity% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, DBV Technologies's stock price is EUR 1 (or $1).
DBV Technologies has current market cap of EUR 181M (or $194M), and EV of EUR 147M (or $158M).
See DBV Technologies trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $158M | $194M | XXX | XXX | XXX | XXX | $-0.40 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, DBV Technologies has market cap of $194M and EV of $158M.
DBV Technologies's trades at 44.5x LTM EV/Revenue multiple, and -1.0x LTM EBITDA.
Analysts estimate DBV Technologies's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for DBV Technologies and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $158M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | XXX | XXX |
| EV/EBITDA | -2.2x | XXX | XXX | XXX |
| P/E | -2.5x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -1.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpDBV Technologies's NTM/LTM revenue growth is 544%
DBV Technologies's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged $0.8M for the same period.
Over next 12 months, DBV Technologies's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate DBV Technologies's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for DBV Technologies and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | XXX | XXX | XXX |
| EBITDA Growth | -19% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | n/a | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.8M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| Opex to Revenue | n/a | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| LTR Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Starpharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Schott Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Nanoform | XXX | XXX | XXX | XXX | XXX | XXX |
| Peptron | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
DBV Technologies acquired XXX companies to date.
Last acquisition by DBV Technologies was XXXXXXXX, XXXXX XXXXX XXXXXX . DBV Technologies acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was DBV Technologies founded? | DBV Technologies was founded in 2002. |
| Where is DBV Technologies headquartered? | DBV Technologies is headquartered in France. |
| How many employees does DBV Technologies have? | As of today, DBV Technologies has 104 employees. |
| Who is the CEO of DBV Technologies? | DBV Technologies's CEO is Mr. Daniel Tasse. |
| Is DBV Technologies publicy listed? | Yes, DBV Technologies is a public company listed on PAR. |
| What is the stock symbol of DBV Technologies? | DBV Technologies trades under DBV ticker. |
| When did DBV Technologies go public? | DBV Technologies went public in 2012. |
| Who are competitors of DBV Technologies? | Similar companies to DBV Technologies include e.g. LTR Pharma, Starpharma, Schott Pharma, Nanoform. |
| What is the current market cap of DBV Technologies? | DBV Technologies's current market cap is $194M |
| What is the current revenue of DBV Technologies? | DBV Technologies's last 12-month revenue is $3.5M. |
| What is the current EBITDA of DBV Technologies? | DBV Technologies's last 12-month EBITDA is -$156M. |
| What is the current EV/Revenue multiple of DBV Technologies? | Current revenue multiple of DBV Technologies is 44.5x. |
| What is the current EV/EBITDA multiple of DBV Technologies? | Current EBITDA multiple of DBV Technologies is -1.0x. |
| Is DBV Technologies profitable? | Yes, DBV Technologies is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
